Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is poised for continued growth with their innovative, data-driven medicine platform and strong presence in the US market. With top-performing applications in heme, solid tumor, and rare disease, a healthy backlog of revenue and plans for expanding their customer base, SOPH is expected to reach positive adjusted EBITDA in 2027. The company's estimated price target of $8, based on a multiple of 6.3x on their projected 2027 revenue of $109M, could potentially see upside with new customer wins and potential large pharma deals.

Bears say

Sophia Genetics is heavily reliant on deals with biopharma companies, like the recently renewed multi-year extension with AstraZeneca, and while there is potential for future extensions, the terms and size of these deals are not disclosed. Their pipeline is growing, but with only 70 customers signed to date and a decline in revenue per analysis, it is uncertain if this will translate into significant revenue growth. Additionally, profitability is not guaranteed in the medium term, making SOPH a risky investment option.

SOPH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 2 analysts, SOPH has a Strong Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.